Health Canada has granted approval to Novartis to market Afinitor everolimus as a treatment for postmenopausal women with hormone receptorpositive HER2negative advanced breast cancer in combination wi…
AstraZeneca has commenced Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON) trial of Faslodex (fulvestrant) injection in breast cancer patients.
ZURICH, Aug 27 (Reuters) - Swiss drugmaker Roche Holding AG said a late-phase trial showed its T-DM1 drug significantly extended the lives of women with advanced breast cancer.
Posted: July 23rd, 2012 | Company/topic: Novartis
Novartis ($NVS) has another notch for Afinitor's belt. The drug won a coveted indication in advanced breast cancer, after data showed it improved progression-free survival by an average of 4.6 months.